antiquity
04-01-2002, 11:40 AM
NeoTherapeutics to Host Conference Call to Discuss Its 10-K Filing
Call set for Tuesday, April 2nd at 10:30 a.m. Eastern time
IRVINE, Calif., April 1 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) will hold a conference call on Tuesday, April 2nd at 10:30 am (Eastern) / 7:30 a.m. (Pacific), to discuss its 10-K filing.
Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics, will host the call.
To access the call please dial (888) 552-7850 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on the company's website at www.neot.com (http://www.neot.com).
NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com (http://www.neot.com).
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
(508) 647-9782, ext. 15
INVESTOR RELATIONS
John McManus
NeoTherapeutics, Inc.
(949) 788-6700, ext. 247
Call set for Tuesday, April 2nd at 10:30 a.m. Eastern time
IRVINE, Calif., April 1 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT) will hold a conference call on Tuesday, April 2nd at 10:30 am (Eastern) / 7:30 a.m. (Pacific), to discuss its 10-K filing.
Alvin J. Glasky, Ph.D., Chairman and Chief Executive Officer of NeoTherapeutics, will host the call.
To access the call please dial (888) 552-7850 approximately ten minutes prior to the scheduled start time. A replay of the call will be available on the company's website at www.neot.com (http://www.neot.com).
NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com (http://www.neot.com).
This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission.
Contacts:
MEDIA RELATIONS
Jon Siegal
Ronald Trahan Associates (RTA) Inc.
(508) 647-9782, ext. 15
INVESTOR RELATIONS
John McManus
NeoTherapeutics, Inc.
(949) 788-6700, ext. 247